Stonnington Group’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Stonnington Group’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	$970K	Buy	+10,100	New	+$593K	0.25%	93

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Stonnington Group's RETA Position: Q1 2023 in Review

Stonnington Group opened a new position in Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2023: 10,100 shares worth $970K. The stake represents 0.25% of the portfolio and ranks #93 among its holdings.

205 funds tracked by Wall St. Rank hold RETA as of Q1 2023.

Stonnington Group held 10,100 shares of Reata Pharmaceuticals, Inc. Class A Common Stock worth $970K as of Q1 2023.
Reata Pharmaceuticals, Inc. Class A Common Stock was a new Stonnington Group position in Q1 2023.
Reata Pharmaceuticals, Inc. Class A Common Stock made up 0.25% of Stonnington Group's portfolio in Q1 2023, its #93 holding.
205 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2023.

Based on Stonnington Group's 13F filing for Q1 2023, filed 14 Apr 2023.